Neuroanatomy of Down Syndrome *in vivo*: A Model of Preclinical Alzheimer's Disease

Stefan J. Teipel,^{1,2} and Harald Hampel¹

Received 6 June 2005—Final 17 Aug. 2005

Aging in Down syndrome (DS) is accompanied by neuropathological features of Alzheimer's disease (AD). Therefore, DS has been proposed as a model to study predementia stages of AD. MRI-based measurement of grey matter atrophy is an *in vivo* surrogate marker of regional neuronal density. A range of neuroimaging studies have described the macroscopic neuroanatomy of DS. Recent studies using sensitive quantitative measures of region-specific atrophy based on high-resolution MRI suggest that age-related atrophy in DS resembles the pattern of brain atrophy in early stages of AD. The pattern of atrophy determined in predementia DS supports the notion that AD-type pathology leads to neuronal degeneration not only in allocortical, but also in neocortical brain areas before onset of clinical dementia. This has major implications for our understanding of the onset and progression of AD-type pathology both in DS and in sporadic AD.

KEY WORDS: Alzheimer's disease; atrophy; cerebral cortex; down syndrome; morphometry; MRI.

THE NEUROPATHOLOGY OF DS AS A MODEL FOR PRECLINICAL ALZHEIMER'S DISEASE

Subjects with Down syndrome (DS) older than 40 years show an age-related cognitive impairment with early memory involvement followed by a linear decline in non-memory cognitive function (Alexander *et al.*, 1997; Lai and Williams, 1989; Schapiro, *et al.*, 1992). Cognitive impairment progresses to a dementia syndrome resembling Alzheimer's disease (AD) (Alexander *et al.*, 1997; Evenhuis, 1990; Lai and Williams, 1989; Schapiro, *et al.*, 1992). Prevalence of dementia has been estimated to reach 5% to 10% until the fifth decade of life and 40% to 50% by the sixth decade of life in DS (Evenhuis, 1990; Lai and Williams, 1989). Postmortem studies show that at 40 years of age virtually all DS subjects have

criteria for AD (Mann et al., 1984; Wisniewski et al., 1985a, b). Similar to patients with sporadic AD, elderly DS subjects show cerebral atrophy, deposition of A β protein in extracellular senile plaques and perivascular amyloid (amyloid angiopathy), intraneuronal neurofibrillary tangles (NFT) and extracellular neuritic plaques and neuropil threads (Jellinger and Bancher, 1998; Mann, 1988). Aß protein derives from atypical splicing of an ubiquitous transmembrane protein, the amyloid precursor protein, which is coded on chromosome 21 (Vassar, 2005). Neuritic changes arise from the formation of paired helical filaments (PHF) containing polymerized hyperphosphorylated tau protein triplets and cause disruption of the neuronal cytoskeleton with loss of synapses and neurons and altered cortico-cortical connectivity, leading to disconnection of the cerebral cortex (Morrison et al., 1986). Neuropathological changes in sporadic AD follow a specific sequence starting in transentorhinal and entorhinal cortex in preclinical stages, later spreading to the hippocampus and involving neocortical association regions in more advanced stages of disease. Primary sensorimotor areas are relatively spared even at severe stages of AD

neuropathological lesions that meet the pathological

¹ Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section, Department of Psychiatry, Ludwig–Maximilian University, Munich, Germany.

² To whom correspondence should be addressed at Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia and Neuroimaging Section, Department of Psychiatry, Ludwig-Maximilian University, Nussbaumstr. 7, 80336 Munich, Germany. Tel.: +1149-89-5160-5860; Fax: +1149-89-5160-5865; e-mail: stefan.teipel@med.uni-muenchen.de

(Braak *et al.*, 1997). A subcortical area typically affected is the cholinergic nucleus basalis Meynert in the basal forebrain (Mesulam, 2004; Teipel *et al.*, 2005). Although the role of plaques and NFT in the pathogenesis of AD remains undetermined, clinico-pathological studies have shown that both lesions, if present in sufficient numbers, particularly in the neocortex, are the best morphological marker for AD. Recent studies on neuronal death in AD have indicated only an indirect relationship between neuronal loss and both $A\beta$ deposition and NFTs. Therefore, both AD markers appear to increase the risk of cells to degenerate, but are not the sole cause of the degenerative process in AD.

DS subjects can exhibit significant amyloid deposition in the cerebral cortex already in their third or fourth decade of life (Ikeda et al., 1989; Rumble et al., 1989). Earliest pathological changes are thought to occur in the medial temporal lobe, after which they are found in neocortical association regions by age of 40 (Hof et al., 1995; Hyman et al., 1995; Mann and Esiri, 1989; Sadowski et al., 1999). An important factor for the development of the neuropathological and clinical phenotype of AD in elderly DS subjects is an increased amyloid burden due to an extra copy of the amyloid precursor protein gene on chromosome 21 (Rumble et al., 1989). The laminar and regional cortical distribution of amyloid and neurofibrillary pathology and neuronal loss closely resembles that of AD. On this basis, DS has been proposed as a model to study the predementia stages of AD (Mann, 1988). There are, however, dissimilarities between both pathologies. Pyramidal neuron abnormalities with reduced dendritic arborization, decreased numbers of spines, spine atrophy and anomalies of spine orientation are already present in infancy and fetal stages of DS (Becker et al., 1991b). Additionally, there are cytoskeletal abnormalities in DS (Mann et al., 1989). These developmental abnormalities make the brain of DS subjects vulnerable for any type of lesions and might contribute to the early onset of dementia in DS subjects. Therefore, the use of DS as a predementia model of AD has to take into account that developmental abnormalities and DS-specific degenerative processes contribute to the neuropathological substrate of dementia in DS.

METHODOLOGICAL BASIS OF MRI ANALYSIS TECHNIQUES

MRI-based measurement of regional brain atrophy can provide an *in vivo* estimate of neuronal

loss in neurodegenerative disease. This has specifically been shown for hippocampus atrophy as a measure of allocortical neuronal loss in AD (Bobinski et al., 2000; Jack et al., 2002; Nagy et al., 1996). There are no clinical-pathological correlational studies for other MRI-based volumetric measurements, such as entorhinal cortex, cortical gray matter volume or corpus callosum, but in vivo estimates of atrophy derived from MRI-based measurements in areas other than the hippocampus agree with the distribution of neuronal loss and neurofibrillary pathology in postmortem studies in AD (Chetelat and Baron, 2003; Nagy et al., 1999; Smith, 2002; Weis et al., 1991a). Therefore, MRI-based measurement of regional brain atrophy may also be useful in elderly DS subjects to determine brain atrophy related to AD-type pathology. Based on the evidence from neuropathological studies these changes can be interpreted as in vivo marker of progressive ADrelated neuron loss. As structural MRI has no known side effects in patients without ferromagnetic implants, it allows repeated examinations over time to study the progression of regional atrophy. Volumetric assessments are based on three-dimensional T1 weighted MRI sequences with a spatial resolution of about 1 mm in all three axes. Acquisition of such a sequence takes about 10-15 min on a 1.5 Tesla scanner. In recent years, 3-T scanners became more widely available so that in the near future volumetric studies will use T1 weighted sequences at 3-T with higher resolution and higher signal to noise ratio.

A wide array of techniques has been developed to determine the extent of regional brain atrophy from volumetric MRI data: (i) visual rating scales, (ii) observer-driven manual volumetry (Fig. 1) and (iii) automated voxel-based techniques (Fig. 2).

Visual rating scales are easily applicable at the cost of relatively low inter-rater reliability (Frisoni et al., 2003). Moreover, they are limited to few anatomical features, like gross brain atrophy, ventricular enlargement or hippocampus atrophy. They are useful for the assessment of individual brain atrophy in clinical routine. Manual volumetric measures are time-consuming, but provide much higher inter-rater reliability. Like visual ratings, manual volumetric measures are limited to few anatomical features. In contrast, automated morphometric techniques provide fast and reliable segmentation of a multitude of anatomical features within a spatial resolution at voxel-level (Ashburner and Friston, 2000). However, all automated techniques are prone to artifacts induced by differences in image quality leading to

Neuroanatomy of Down syndrome in vivo



Fig. 1. Manual volumetric measures. (a) Hippocampus/amygdala volumetry. Left: sagittal MRI section through the right hippocampus with the hippocampus (light blue) and the amygdala (turquoise, anterior to hippocampus) manually labeled. Right: three-dimensional reconstruction of the hippocampus and amygdala from manually labeled volumetric MRI scans (Hampel *et al.*, 2002b). (b) Corpus callosum. Midsagittal MRI section through the brain with the corpus callosum and five corpus callosum subregions manually outlined (Teipel *et al.*, 2002a). C1 – Rostrum; C2 – anterior truncus; C3 – middle truncus; C4 – posterior truncus and isthmus; C5 – Splenium. (c) Lobar volumes. Upper row: Schematic drawing of lobar borders on the sagittal surface of the brain: central sulcus between frontal and parietal lobes; lateral sulcus between frontal and temporal lobes; geometrical construction based on the sulcus parieto–occipitalis and the most posterior point of the lateral sulcus between parietal, temporal and occipital lobes. Lower row: Lobar borders projected on the lateral surface projection of the brain from a volumetric MRI scan (Bokde *et al.*, 2002).

local misregistration (Bookstein, 2001). This is particularly true for multicenter data, so that few studies so far have tried to pool MRI data from several centers for automated morphometric analysis. Results from automated analysis always should be compared with findings from manual volumetric studies and results from independent samples to assess their validity.

MRI SHOWS THE NEUROANATOMY OF DS *IN VIVO*

The neuroanatomy of DS has two dimensions: (i) the developmental abnormality of the brain constituting an important part of the DS phenotype and (ii) the progressive brain atrophy with advancing age in DS adults that is superimposed on the developmental abnormality and is believed to result partly from AD-type pathological changes. In recent years, autopsy data on the neuroanatomy of DS have been complemented by an increasing body of evidence from *in vivo* structural imaging using CT and to a larger extent MRI.

MRI Shows the Developmental Abnormalities of the DS Brain

The brain of DS subjects is characterized by several postmortem macroscopic features which are related to pre- and post-natal abnormalities in synaptogenesis leading to retardation of brain growth (Schmidt-Sidor *et al.*, 1990): lower brain weight and brachycephaly, with a small cerebellum, frontal and temporal lobes, reduced number and depth of the cerebral sulci, and a narrow superior temporal gyrus



Fig. 2. The processing stream of classical VBM An MRI volume of the brain in native space (a) is transformed into standard space according to the Talairach and Tournoux coordinate system (Talairach and Tournoux, 1988) using a non-linear transformation algorithm in reference to a standard brain template (b), resulting in an MRI brain volume in standard space (c). This volume is segmented into cerebrospinal fluid (d), gray matter (e) and white matter (f) maps. After smoothing with a Gaussian kernel (g), MRI volumes in standard space are pooled across several subjects and can be subjected to statistical analysis on a voxel by voxel basis, typically using the general linear model framework (matrix h).

(Becker *et al.*, 1991a; Coyle *et al.*, 1986; Wisniewski, 1990). Even after controlling for body size, brain volume is smaller in DS subjects compared to age-matched normal controls (Raz *et al.*, 1995; Yoshimura *et al.*, 1990). MRI studies show a consistent phenotype of regional brain abnormalities compared to age-matched non-DS subjects. Table I gives an overview on MRI volumetric findings in young and non-demented adult DS subjects compared to age-matched non-DS controls.

Consistent with postmortem data, overall brain volume is reduced in DS subjects, including cerebellum and cerebral gray and white matter. Hippocampus volume is disproportionally reduced, whereas amygdala volume reductions do not exceed the overall reduction of brain size. Interestingly, parahippocampal gyrus volume is relatively larger in DS (Kesslak *et al.*, 1994; Raz *et al.*, 1995). This might be related to developmental abnormalities in neurogenesis. Only one study investigated the relative reductions of cerebral lobe volumes in DS (Pinter *et al.*, 2001b), one study investigated volumes of anterior and posterior cortex (Jernigan, et al., 1993). Cerebral volume reductions were predominant in frontal and occipital lobes, as well as in planum temporale and superior temporal gyrus. Absolute volumes of temporal and parietal lobes were reduced, but these effects were no more significant after adjustment for overall brain size. The relative preservation of temporal lobe volume was related to a significantly larger white matter volume after adjustment for brain size. The authors speculated that this might reflect a selective abnormality in white matter maturation. An additional factor, however, may be methodological difficulties in determining the posterior borders of the temporal lobes on MRI scans, as their method relied on a semiautomated parcellation of the brain using a pediatric template. It is not clear from the study whether the use of a normal pediatric brain template might have introduced a bias in defining the lobe borders on the differently proportioned brains of the DS subjects. In two previous studies, subcortical gray matter structures (basal ganglia, thalamus) were normal in DS (Jernigan et al., 1993; Pinter et al., 2001b).

Region	Effect	Reference
Total brain volume Gray matter White matter		Pinter et al. (2001b), Weis et al., (1991b)
Total cerebral volume Gray matter White matter		Pinter et al. (2001b), Weis et al. (1991b)
Cerebellar volume	J	Pinter et al. (2001b)
Hippocampus	\downarrow after adjustment for overall brain volume	Pinter <i>et al.</i> (2001a), Pearlson <i>et al.</i> (1998), Aylward <i>et al.</i> (1999), Raz <i>et al.</i> (1995)
Amygdala	\downarrow not different after adjustment for overall brain volume	Pinter et al. (2001a), Aylward et al. (1999)
Parahippocampal gyrus Frontal lobe	 ↑ after adjustment for overall brain volume ↔ after adjustment for overall brain volume ↓ Anterior cortex, including frontal and anterior temporal lobe, after adjustment for total cerebral gray matter volume 	Raz et al. (1995), Kesslak et al. (1994) Pinter et al. (2001b) Jernigan et al. (1993)
Parietal lobe	 ↑ after adjustment for overall brain ↑ Posterior cortex, including superior parietal lobes, after adjustment for total cerebral gray matter volume 	Pinter <i>et al.</i> (2001b) Jernigan <i>et al.</i> (1993)
Temporal lobe	↑ after adjustment for overall brain volume	Pinter et al. (2001b)
Occipital lobe	\leftrightarrow after adjustment for overall brain volume	Pinter et al. (2001b)
Superior temporal gyrus	\leftrightarrow after adjustment for overall brain volume	Pinter et al. (2001b), Frangou et al. (1997)
Planum temporale	\downarrow after adjustment for overall brain volume	Frangou et al. (1997)
Lenticular nucleus	\uparrow after adjustment for total cerebral gray matter volume, \leftrightarrow absolute volumes	Jernigan et al. (1993), Pinter et al. (2001b)
Diencephalon	↑ after adjustment for total cerebral gray	Jernigan et al. (1993), Pinter et al. (2001b)
(thalamus and hypothalamus)	matter volume, \leftrightarrow absolute volumes	
Ventricles	↑	Pearlson et al. (1998)
Corpus callosum	\downarrow (Rostrum)	Wang et al. (1992)

Table I. MRI Findings on Developmental Abnormalities of the Brain in DS

Summary of MRI findings in different brain areas:

 \uparrow – increase of volume

 \downarrow – decrease of volume

 \leftrightarrow – no volume change.

MRI Shows Effects of Aging on the DS Brain

Potential Study Designs

Age-related changes of brain morphometry in elderly non-demented DS subjects are thought to represent the effect of preclinical AD-type pathology. However, the effects of aging are superimposed on preexisting developmental brain abnormalities in DS. Therefore, the design of an MRI study may depend upon the specific question to be answered. Not every design is able to differentiate between developmental abnormalities and age-related changes of the brain in DS. Three basic designs can be distinguished:

 (i) studies comparing elderly DS subjects with elderly non-DS subjects are suitable for the description of correlations between regional brain measurements and cognitive abnormalities, but not the differentiation between the contribution of developmental and age-related alterations.

- (ii) studies comparing elderly DS subjects with younger DS subjects can describe age-related alterations in brain morphology possibly linked to AD-type pathology. However, they cannot distinguish between the effects of age and ADtype pathology.
- (iii) studies providing an intra-individual timeline of regional brain atrophy are often difficult to perform due to methodological limitations (changes in scanner hardware over time, selection bias over time due to non-randomly missing subjects), but are the gold standard to determine the effect of AD-type pathology on the DS brain.

MRI Findings on Age Effects in the Medial Temporal Lobes

In recent years, in vivo studies using magnetic resonance imaging (MRI) have investigated agerelated brain atrophy in DS. Several computer assisted tomography (CT) and MRI studies have reported significantly reduced volumes of the hippocampus and adjacent medial temporal lobe structures with advancing age in non-demented DS subjects (Kesslak et al., 1994; Krasuski et al., 2002; Lawlor et al., 2001). Hippocampus and amygdala volumes are significantly correlated with decline of memory function, even after controlling for overall cognitive performance and age (Krasuski et al., 2002). These findings agree with neuropathological evidence of extensive tangle pathology and neuronal loss in entorhinal cortex and hippocampus (Hof et al., 1995; Sadowski et al., 1999) as well as the early decline of memory function in elderly DS subjects.

Two studies found no atrophy of hippocampus and parahippocampal gyrus before onset of dementia. Both studies, however, together with others showed reductions of hippocampus and parahippocampal gyrus volumes in elderly demented DS subjects compared to non-demented, younger DS subjects (Aylward *et al.*, 1999; Pearlson *et al.*, 1998; Raz *et al.*, 1995). In summary, hippocampus volume declines with age, most likely even before onset of dementia. This decline is superimposed on developmental reductions of hippocampus volume. Parahippocampal gyrus volume declines with age in DS, this decline, however, seems to start from a developmentally relatively spared or even increased parahippocampal volume.

MRI Findings on Age Effects in Neocortical Areas

The most consistent age-related finding in DS subjects outside of the medial temporal lobe in cross-sectional studies was an increase of ventricular volume with age in demented elderly DS subjects (Ikeda and Arai, 2002; Kesslak *et al.*, 1994). There are only few studies focusing on the onset and progression of neocortical atrophy in DS adults. Manual measures of total brain and gray matter volumes showed no significant atrophy before the onset of dementia (Kesslak *et al.*, 1994; Pearlson *et al.*, 1998; Raz, *et al.*, 1995; Schapiro *et al.*, 1989; 1992). However, demented DS subjects showed progressive atrophy of brain gray matter predominantly in temporal lobes, and widening of cerebrospinal fluid spaces in serial

CT examinations (Ikeda and Arai, 2002; Lai and Williams, 1989; Schapiro *et al.*, 1989). It has been suggested that significant brain atrophy occurs only when dementia becomes manifest in older DS subjects (Schapiro *et al.*, 1989). Evidence from AD, however, suggests that regional atrophy precedes onset of clinical dementia not only in the hippocampus, but also neocortical brain regions (Fox *et al.*, 2001; Karas *et al.*, 2004; Pennanen *et al.*, 2005). The lack of predementia neocortical atrophy in DS found in these earlier studies might be related to low sensitivity of the measures employed, particularly CT-based volumetry and visual ratings, a relatively narrow age-range, and small sample sizes.

Recent studies have employed more sensitive markers to detect neocortical atrophy in predementia stages of DS. A potential marker of neocortical degeneration is the corpus callosum (Hampel et al., 2002a). The corpus callosum fibers originate from layer III and V pyramidal neurons in the cerebral cortex (Innocenti, 1986), which are early and specifically affected by AD-type pathology (Morrison et al., 1986; Pearson et al., 1985). Corpus callosum area is reduced both in postmortem examination (Weis et al., 1991a) and in in-vivo MRI studies (Hampel et al., 1998) in AD patients. Corpus callosum area correlates with measures of cortical dysfunction derived from PET and EEG, supporting the notion that corpus callosum atrophy can be used as a marker of neocortical neuronal degeneration in AD (Hampel et al., 2002a; Janowsky et al., 1996; Teipel et al., 1998, 1999, 2002b; Yamauchi, et al., 1993). On this basis, we determined corpus callosum atrophy in 34 DS subjects and 32 healthy control subjects. We found significant atrophy of the corpus callosum even before onset of dementia in DS adults (Teipel et al., 2003). The extent of corpus callosum atrophy in elder compared to younger DS subjects was comparable to that of hippocampus atrophy. The age-related decrease of corpus callosum was most pronounced in the splenium area, representing projections from posterior temporal, superior parietal and occipital cortex (De Lacoste et al., 1985). These findings suggest that loss of inter-hemispheric projecting neurons in posterior association cortex precedes the clinical onset of dementia in DS. Corpus callosum atrophy is a specific marker for the loss of intra-cortical projecting neurons, but has limited spatial resolution. Therefore, in a subsequent study, we used an automated voxel-based approach to determine the extent of regional cortical gray matter loss in predementia stages of DS (Teipel et al., 2004). In recent years, voxel-based morphometry (VBM) has been developed to search the entire brain for morphological changes (Ashburner and Friston, 2000). VBM is observer independent and automated, and therefore highly replicable. It allows for processing of a high number of scans within a relatively short time, and can detect morphological changes throughout the entire brain. Using VBM, we investigated age-related changes of gray matter volume within a DS group (Teipel et al., 2004). Gray matter maps were determined from volumetric T1 weighted MRI scans obtained in coronal orientation on a 1.5-T scanner (General Electric Signa II, Milwaukee). The protocol followed a modification of the previously established processing stream of VBM (Fig. 2) (Good et al., 2001). In a group of 32 DS subjects, age was significantly correlated with decline of cortical gray matter in parietal, frontal and occipital cortex (mainly lingual cortex), as well as temporal lobe and parahippocampal gyrus. The effects were most pronounced in superior parietal lobes, which agrees with the findings of predominant corpus callosum atrophy in the splenium receiving major projections from superior parietal lobes (Fig. 3).

This study only included subjects without dementia, from 25 up to 62 years of age. When

cortical gray matter volumes were correlated with a test of verbal memory, decline in memory performance was correlated with reduced gray matter volume in left superior and middle temporal gyrus, bilateral precuneus, left hippocampus, right middle temporal gyrus, and right middle frontal gyrus. Therefore, even after controlling for age and general cognitive function, correlations between episodic memory and gray matter volume revealed brain areas which are thought to be associated with visual attention (precuneus) (Corbetta et al., 1995), episodic memory encoding (hippocampus) (Greicius et al., 2003; Squire and Zola-Morgan, 1991), episodic memory retrieval (right prefrontal cortex) (Lee, et al., 2000; Rugg et al., 2002) and language (left temporal pole, left lateral temporal cortex, including Wernike's area) (Benson, 1988; Cabeza and Nyberg, 2000). These findings may indicate that impaired memory performance in the DS subjects is related to local morphological brain changes, most likely on the basis of developmental abnormalities or neurodegenerative changes or both. One has, however, to take into account that only non-demented subjects were included which led to a ceiling effect in the memory scores.

MRI findings on age-related brain changes in DS are summarized in Table II.



Region	Effect	Reference	
Non-demented elderly DS subjects			
versus young DS subjects			
Hippocampus	\downarrow	Krasuski et al. (2002) (Kesslak et al., (1994	
Parahippocampal gyrus	\downarrow	Krasuski et al. (2002)	
Corpus callosum	\downarrow (Splenium)	Teipel et al. (2003)	
Total brain volume	\leftrightarrow	Kesslak et al. (1994), Pearlson et al. (1998), Raz et al.	
		(1995), Schapiro et al. (1989, 1992)	
Total gray matter volume	\leftrightarrow	Kesslak et al. (1994), Pearlson et al. (1998), Raz et al.	
		(1995), Schapiro et al. (1989, 1992)	
Demented DS subjects versus			
non-demented DS subjects			
Total brain volume	\downarrow	Kesslak et al. (1994), Pearlson et al. (1998), Raz et al.	
		(1995), Schapiro et al. (1989, 1992)	
Total gray matter volume	\downarrow	Kesslak et al. (1994), Pearlson, et al. (1998), Raz et al.	
		(1995), Schapiro et al. (1989, 1992)	
Frontal cortex	\downarrow	Teipel et al. (2004)	
Temporal lobes	\downarrow	Lai and Williams, (1989), Teipel et al. (2004)	
Parietal cortex	\downarrow	Teipel et al. (2004)	
Hippocampus	\downarrow	Lawlor et al. (2001)	
Parahippocampal gyrus	\downarrow	Krasuski et al. (2002), Teipel et al. (2004)	
Ventricles	↑	Kesslak et al. (1994), Ikeda and Arai, (2002)	

 Table II. MRI Shows Age-related Brain Atrophy in DS

Summary of MRI findings in different brain areas:

 \uparrow – increase of volume

 \downarrow – decrease of volume

 \leftrightarrow – no volume change

Interpretation of MRI Findings and Their Limitations

These findings suggest that, like in AD, regional brain atrophy, including hippocampus, parahippocampus, but also neocortical association areas, accompanies aging in DS and can be detected even before the onset of clinical dementia. The most likely substrate of these macroscopic changes are progressive AD-related pathological changes in the DS brain composed of tangle and plaque accumulation as well as synaptic and neuronal loss. These changes precede the onset of dementia in DS and can be detected *in vivo* using high resolution imaging techniques like hippocampus and corpus callosum volumetry as well as VBM.

There are, however, two caveats to be taken into account for the interpretation of these findings: First, DS is a developmental disorder and therefore any age related changes are superimposed on developmental abnormalities. This is well illustrated by a recent study (White *et al.*, 2003) demonstrating morphological differences between adult non-demented DS subjects and healthy age matched controls using MRI and VBM. DS subjects had reduced gray matter volume in cerebellum, left medial frontal lobe, right superior and middle temporal lobe, and anterior and middle cingulated gyrus. This regional pattern of gray matter changes is clearly distinct from the age effects we found in the non-demented DS subjects using VBM (Teipel et al., 2004). It can, however, not be excluded that age effects are masked by higher variability of brain morphology in brain areas which are severely affected by developmental abnormalities. Second, the resemblance between DS and AD neuropathology is close, but not perfect. Plaque density was found to be higher in many DS subjects compared to AD patients and more widely distributed throughout the cortex (Hof et al., 1995). Additionally, results of several studies suggest cytoskeletal abnormalities in DS (Mann et al., 1989), and overexpression of proteins other than amyloid which may contribute to neurodegeneration (De La Torre et al., 1996; Engidawork and Lubec, 2001). Therefore, the possibility cannot be excluded that age-effects on cortical gray matter in non-demented DS subjects reflect at least partially DS-specific degenerative processes other than AD.

SUMMARY AND PERSPECTIVES

There is conclusive evidence for both, developmental abnormality of neuroanatomy and age associated brain atrophy in DS. An important task for future studies is the quantitative analysis of serial MRI examinations in non-demented elderly DS subjects followed over several years, some of them until conversion into dementia. These data would be very important to distinguish between developmental and age-associated (degenerative) alterations of brain morphology in DS. A wide range of cross-sectional studies, however, provides strong evidence for an independent contribution of age-associated neurodegeneration to progressive brain atrophy, particular in medial temporal lobes and posterior association cortex, the typical predilection areas of sporadic AD. Therefore, MRI investigation of brain aging in DS not only gives new insight in the onset and progression of neurodegenerative changes in DS, but also opens a window into the preclinical stages of AD. The finding of allocortical and neocortical brain atrophy in non-demented elderly DS subjects suggests that both allocortical and neocortical neuronal loss precedes the onset of clinical dementia in AD-type pathology. This has implications for our understanding of the onset of allocortical and neocortical neurodegeneration in AD. In particular, it supports the notion that treatment in AD should be initiated early in the course of the disease in order to rely on intact neuronal systems and even suggests that treatment should precede onset of clinical dementia. This will be even more important once disease modifying treatment approaches become available. From the diagnostic perspective, the findings on neocortical atrophy in predementia stages of DS-related AD suggest that structural MRI analysis should not only involve hippocampal, but also neocortical measures for the early detection of AD-related pattern of brain atrophy.

ACKNOWLEDGMENTS

We thank Dr. Michael Ewers (LMU Munich) for critical reading of the manuscript. Part of this work was supported by grants of the Medical Faculty of the Ludwig–Maximilian University (Munich, Germany) to S.J.T., of the Hirnliga e. V. (Nürmbrecht, Germany) to S.J.T. and H.H., and by the German Competency Network on Dementias (Kompetenznetz Demenzen) funded by the Bundesministerium für Bildung und Forschung (BMBF), Germany.

REFERENCES

- Alexander, G. E., Saunders, A. M., Szczepanik, J., Strassburger, T. L., Pietrini, P., and Dani, A. et al., (1997). Relation of age and apolipoprotein E to cognitive function in Down syndrome adults. *Neuroreport* 8:1835–1840.
- Ashburner, J., and Friston, K. J. (2000). Voxel-based morphometry-the methods. *Neuroimage* 11:805–821.
- Aylward, E. H., Li, Q., Honeycutt, N. A., Warren, A. C., Pulsifer, M. B., and Barta, P. E. (1999). MRI volumes of the hippocampus and amygdala in adults with Down's syndrome with and without dementia. *Am. J. Psychiatry* **156**:564–568.
- Becker, L., Mito, T., Takashima, S., and Onodera, K. (1991a). Growth and development of the brain in Down syndrome. In C. Epstein (ed.), *The Morphogenesis of Down Syndrome*. New York: Wiley-Liss, pp. 133–152.
- Becker, L., Mito, T., Takashima, S., and Onodera, K. (1991b). Growth and development of the brain in Down syndrome. *Prog. Clin. Biol. Res.* 373:133–152.
- Benson, D. F. (1988). Classical syndromes of aphasia. In F. Foller and J. Grafman (eds.), *Handbook of Neuropsychology*. Amsterdam: Elsevier.
- Bobinski, M., de Leon, M. J., Wegiel, J., Desanti, S., Convit, A., and Saint Louis, L. A. (2000). The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. *Neuroscience* 95:721–725.
- Bokde, A. L., Teipel, S. J., Zebuhr, Y., Leinsinger, G., Gootjes, L., and Schwarz, R. (2002). A new rapid landmark-based regional MRI segmentation method of the brain. J. Neurol. Sci. 194:35–40.
- Bookstein, F. L. (2001). "Voxel-based morphometry" should not be used with imperfectly registered images. *Neuroimage*. 14:1454–1462.
- Braak, H., Griffing, K., and Braak, E. (1997). Neuroanatomy of Alzheimer's disease. *Alzheimer's Research* 3:235–247.
- Cabeza, R., and Nyberg, L. (2000). Imaging cognition II: an empirical review of 275 PET and fMRI studies. J. Cogn. Neurosci. 12:1–47.
- Chetelat, G., and Baron, J. C. (2003). Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. *Neuroimage* 18:525–541.
- Corbetta, M., Shulman, G. L., Miezin, F. M., and Petersen, S. E. (1995). Superior parietal cortex activation during spatial attention shifts and visual feature conjunction. *Science* 270:802–805.
- Coyle, J. T., Oster-Granite, M. L., and Gearhart, J. D. (1986). The neurobiologic consequences of Down syndrome. *Brain Res. Bull.* 16:773–787.
- De La Torre, R., Casado, A., Lopez-Fernandez, E., Carrascosa, D., Ramirez, V., and Saez, J. (1996). Overexpression of copper-zinc superoxide dismutase in trisomy 21. *Experientia* 52:871–873.
- De Lacoste, M. C., Kirkpatrick, J. B., and Ross, E. D. (1985). Topography of the human corpus callosum. J. Neuropath. Exper. Neurol. 44:578–591.
- Engidawork, E., and Lubec, G. (2001). Protein expression in Down syndrome brain. *Amino Acids* **21**:331–361.
- Evenhuis, H. M. (1990). The natural history of dementia in Down's syndrome. Arch. Neurol. 47:263–267.
- Fox, N. C., Crum, W. R., Scahill, R. I., Stevens, J. M., Janssen, J. C., and Rossor, M. N. (2001). Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. *Lancet* 358:201–205.
- Frangou, S., Aylward, E., Warren, A., Sharma, T., Barta, P., and Pearlson, G. (1997). Small planum temporale volume in Down's syndrome: a volumetric MRI study. *Am. J. Psychiatry*. **154**:1424–1429.

- Frisoni, G. B., Scheltens, P., Galluzzi, S., Nobili, F. M., Fox, N. C., and Robert, P. H. (2003). Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J. Neurol. Neurosurg. Psychiat. 74:1371– 1381.
- Good, C. D., Johnsrude, I. S., Ashburner, J., Henson, R. N., Friston, K. J., and Frackowiak, R. S. (2001). A voxel-based morphometric study of ageing in 465 normal adult human brains. *Neuroimage* 14:21–36.
- Greicius, M. D., Krasnow, B., Boyett-Anderson, J. M., Eliez, S., Schatzberg, A. F., and Reiss, A. L. (2003). Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. *Hippocampus* 13:164–174.
- Hampel, H., Teipel, S. J., Alexander, G. E., Horwitz, B., Teichberg, D., and Schapiro, M. B. (1998). Corpus callosum atrophy is a possible indicator of region- and cell type-specific neuronal degeneration in Alzheimer disease: a magnetic resonance imaging analysis. Arch. Neurol. 55:193–198.
- Hampel, H., Teipel, S. J., Alexander, G. E., Pogarell, O., Rapoport, S. I., and Moller, H. J. (2002a). In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J. Neural. Transm. 109:837–855.
- Hampel, H., Teipel, S. J., Bayer, W., Alexander, G. E., Schwarz, R., and Schapiro, M. B. (2002b). Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. J. Neurol. Sci. 194:15–19.
- Hof, P. R., Bouras, C., Perl, D. P., Sparks, D. L., Mehta, N., and Morrison, J. H. (1995). Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch. Neurol. 52:379–391.
- Hyman, B. T., West, H. L., Rebeck, G. W., Lai, F., and Mann, D. M. (1995). Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.. Arch. Neurol. 52:373–378.
- Ikeda, M., and Arai, Y. (2002). Longitudinal changes in brain CT scans and development of dementia in Down's syndrome. *Eur. Neurol.* 47:205–208.
- Ikeda, S., Yanagisawa, N., Allsop, D., and Glenner, G. G. (1989). Evidence of amyloid beta-protein immunoreactive early plaque lesions in Down's syndrome brains. *Lab. Invest.* 61:133– 137.
- Innocenti, G. M. (1986). General organization of callosal connections in the cerebral cortex. In E. G. Jones and A. Peters (eds.), *Cerebral Cortex: Sensory Motor Areas and Aspects of Cortical Connectivity*. New York, NY: Plenum Publishing Corp., pp. 291–353.
- Jack, C. R. Jr., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., and O'Brien, P. C. (2002). Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. *Neurology* 58:750–757.
- Janowsky, J. S., Kaye, J. A., and Carper, R. A. (1996). Atrophy of the corpus callosum in Alzheimer's disease versus healthy aging. J. Am. Ger. Soc. 44:798–803.
- Jellinger, K. A., and Bancher, C. (1998). Neuropathology of Alzheimer's disease: a critical update. J. Neural. Transm. Suppl. 54:77–95.
- Jernigan, T. L., Bellugi, U., Sowell, E., Doherty, S., and Hesselink, J. R. (1993). Cerebral morphologic distinctions between Williams and Down syndromes. *Arch. Neurol.* 50:186–191.
- Karas, G. B., Scheltens, P., Rombouts, S. A., Visser, P. J., van Schijndel, R. A., and Fox, N. C. (2004). Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. *Neuroimage* 23:708–716.

- Kesslak, J. P., Nagata, S. F., Lott, I., and Nalcioglu, O. (1994). Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down's syndrome. *Neurology* 44:1039–1045.
- Krasuski, J. S., Alexander, G. E., Horwitz, B., Rapoport, S. I., and Schapiro, M. B. (2002). Relation of medial temporal lobe volumes to age and memory function in nondemented adults with Down's syndrome: implications for the prodromal phase of Alzheimer's disease. *Am. J. Psychiatry* **159**:74–81.
- Lai, F., and Williams, R. S. (1989). A prospective study of Alzheimer disease in Down syndrome. Arch. Neurol. 46:849–853.
- Lawlor, B. A., McCarron, M., Wilson, G., and McLoughlin, M. (2001). Temporal lobe-oriented CT scanning and dementia in Down's syndrome. *Int. J. Geriatr. Psychiatry* 16:427–429.
- Lee, A. C., Robbins, T. W., and Owen, A. M. (2000). Episodic memory meets working memory in the frontal lobe: functional neuroimaging studies of encoding and retrieval. *Crit. Rev. Neurobiol.* 14:165–197.
- Mann, D. M. (1988). The pathological association between Down syndrome and Alzheimer disease. *Mech. Ageing Dev.* 43:99– 136.
- Mann, D. M., and Esiri, M. M. (1989). The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J. Neurol. Sci. 89:169–179.
- Mann, D. M., Prinja, D., Davies, C. A., Ihara, Y., Delacourte, A., and Defossez, A. (1989). Immunocytochemical profile of neurofibrillary tangles in Down's syndrome patients of different ages. J. Neurol. Sci. 92:247–260.
- Mann, D. M. A., Yates, P. O., and Marcyniuk, B. (1984). Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. *Neuropath. Appl. Neurobiol.* 10:185–207.
- Mesulam, M. (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? *Learn. Mem.* 11:43–49.
- Morrison, J. H., Scherr, S., Lewis, D. A., Campbell, M. J., and Bloom, F. E. (1986). The laminar and regional distribution of neocortical somatostatin and neuritic plaques: implications for Alzheimer's disease as a global neocortical disconnection syndrome. In A. B. Scheibel and A. F. Weschler (eds.), *The Biological Substrates of Alzheimer's Disease*. New York, NY: Academic Press, pp. 115–131.
- Nagy, Z., Hindley, N. J., Braak, H., Braak, E., Yilmazer-Hanke, D. M., and Schultz, C. (1999). The progression of Alzheimer's disease from limbic regions to the neocortex: clinical, radiological and pathological relationships. *Dement. Geriatr. Cogn. Disord.* 10:115–120.
- Nagy, Z., Jobst, K. A., Esiri, M. M., Morris, J. H., King, E. M.-F., and MacDonald, B. (1996). Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathological correlations using three sets of pathologic diagnostic criteria. *Dementia* 7:76–81.
- Pearlson, G. D., Breiter, S. N., Aylward, E. H., Warren, A. C., Grygorcewicz, M., and Frangou, S. (1998). MRI brain changes in subjects with Down syndrome with and without dementia. *Dev. Med. Child Neurol.* 40:326–334.
- Pearson, R. C. A., Esiri, M. M., Hiorns, R. W., Wilcock, G. K., and Powell, T. P. S. (1985). Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer's disease. *Proc. Natl. Acad. Sci. USA.* 82:4531– 4534.
- Pennanen, C., Testa, C., Laakso, M. P., Hallikainen, M., Helkala, E. L., and Hanninen, T. (2005). A voxel based morphometry study on mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry. 76:11–14.
- Pinter, J. D., Brown, W. E., Eliez, S., Schmitt, J. E., Capone, G. T., and Reiss, A. L. (2001a). Amygdala and hippocampal volumes in children with Down syndrome: a high-resolution MRI study. *Neurology* 56:972–974.

Neuroanatomy of Down syndrome in vivo

- Pinter, J. D., Eliez, S., Schmitt, J. E., Capone, G. T., and Reiss, A. L. (2001b). Neuroanatomy of Down's syndrome: a high-resolution MRI study. Am. J. Psychiatry 158:1659–1665.
- Raz, N., Torres, I. J., Briggs, S. D., Spencer, W. D., Thornton, A. E., and Loken, W. J. (1995). Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. *Neurology* 45:356–366.
- Rugg, M. D., Otten, L. J., and Henson, R. N. (2002). The neural basis of episodic memory: evidence from functional neuroimaging. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 357:1097– 1110.
- Rumble, B., Retallack, R., Hilbich, C., Simms, G., Multhaup, G., and Martins, R. (1989). Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. *N. Engl. J. Med.* 320:1446–1452.
- Sadowski, M., Wisniewski, H. M., Tarnawski, M., Kozlowski, P. B., Lach, B., and Wegiel, J. (1999). Entorhinal cortex of aged subjects with Down's syndrome shows severe neuronal loss caused by neurofibrillary pathology. *Acta Neuropathol.* 97:156–164.
- Schapiro, M. B., Haxby, J. V., and Grady, C. L. (1992). Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology. *Neurobiol. Aging* 13:723–734.
- Schapiro, M. B., Luxenberg, J. S., Kaye, J. A., Haxby, J. V., Friedland, R. P., and Rapoport, S. I. (1989). Serial quantitative CT analysis of brain morphometrics in adult Down's syndrome at different ages. *Neurology* **39**:1349–1353.
- Schmidt-Sidor, B., Wisniewski, K. E., Shepard, T. H., and Sersen, E. A. (1990). Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. *Clin. Neuropathol.* 9:181–190.
- Smith, A. D. (2002). Commentary: Imaging the progression of Alzheimer pathology through the brain. PNAS 99:4135–4137.
- Squire, L. R., and Zola-Morgan, S. (1991). The medial temporal lobe memory system. *Science* **253**:1380–1386.
- Talairach, J., and Tournoux, P. (1988). Co-Planar Stereotaxic Atlas of the Human Brain. New York: Thieme.
- Teipel, S. J., Alexander, G. E., Schapiro, M. B., Moller, H. J., Rapoport, S. I., and Hampel, H. (2004). Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. *Brain* 127:811–824.
- Teipel, S. J., Bayer, W., Alexander, G. E., Zebuhr, Y., Teichberg, D., and Kulic, L. (2002a). Progression of corpus callosum atrophy in Alzheimer disease. *Arch. Neurol.* 59:243–248.
- Teipel, S. J., Bayer, W., Alexander, G. E., Zebuhr, Y., Teichberg, D., and Kulic, L. (2002b). Progression of Corpus Callosum Atrophy in Alzheimer's disease. *Arch. Neurol.* 59:243–248.
- Teipel S. J., Flatz W. H., Heinsen H., Bokde A. L. W., Schoenberg S. O., Stöckel S., et al. (2005). Measurement of basal forebrain atrophy in AD using MRI. Brain. 128:2626–2644.

- Teipel, S. J., Hampel, H., Alexander, G. E., Schapiro, M. B., Horwitz, B., and Teichberg, D. (1998). Dissociation between white matter pathology and corpus callosum atrophy in Alzheimer's disease. *Neurology* 51:1381–1385.
- Teipel, S. J., Hampel, H., Pietrini, P., Alexander, G. E., Horwitz, B., and Daley, E. (1999). Region specific corpus callosum atrophy correlates with regional pattern of cortical glucose metabolism in Alzheimer's disease. *Arch. Neurol.* 56:467–473.
- Teipel, S. J., Schapiro, M. B., Alexander, G. E., Krasuski, J. S., Horwitz, B., and Hoehne, C. (2003). Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. *Am. J. Psychiatry* 160:1870–1878.
- Vassar, R. (2005). beta-Secretase, APP and Abeta in Alzheimer's disease. Subcell. Biochem. 38:79–103.
- Wang, P. P., Doherty, S., Hesselink, J. R., and Bellugi, U. (1992). Callosal morphology concurs with neurobehavioral and neuropathological findings in two neurodevelopmental disorders. *Arch. Neurol.* 49:407–411.
- Weis, S., Jellinger, K., and Wenger, E. (1991a). Morphometry of the corpus callosum in normal aging and Alzheimer's disease. *J. Neural. Transm.* 33(Suppl):35–38.
- Weis, S., Weber, G., Neuhold, A., and Rett, A. (1991b). Down Syndrome: MR quantification of brain structures and comparison with normal control subjects. *AJNR* 12:1207–1211.
- White, N. S., Alkire, M. T., and Haier, R. J. (2003). A voxel-based morphometric study of nondemented adults with Down Syndrome. *Neuroimage* 20:393–403.
- Wisniewski, K. E. (1990). Down syndrome children often have brain with maturation delay, retardation of growth, and cortical dysgenesis. Am. J. Med. Genet. Suppl. 7:274–281.
- Wisniewski, K. E., Dalton, A. J., McLachlan, C., Wen, G. Y., and Wisniewski, H. M. (1985a). Alzheimer's disease in Down's syndrome: clinicopathologic studies. *Neurology* 35:957–961.
- Wisniewski, K. E., Wisniewski, H. M., and Wen, G. Y. (1985b). Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. *Ann. Neurol.* 17:278–282.
- Yamauchi, H., Fukuyama, H., Harada, K., Nabatame, H., Ogawa, M., and Ouchi, Y. (1993). Callosal atrophy parallels decreased cortical oxygen metabolism and neuropsychological impairment in Alzheimer's disease. *Arch. Neurol.* 50:1070–1074.
- Yoshimura, N., Kubota, S., Fukushima, Y., Kudo, H., Ishigaki, H., and Yoshida, Y. (1990). Down's syndrome in middle age. Topographical distribution and immunoreactivity of brain lesions in an autopsied patient. Acta Pathol. Jpn. 40:735-743.

Edited by Pierre L. Roubertoux